Namaste, We're Tanner
We improve lives by increasing access to medicines around the world.
YES, WE CAN
Our goal is simple, to improve lives by increasing access to medicines around the world.
We deliver solutions for organizations in the global healthcare network, removing barriers and implementing programs so they can:
- Provide access to medicines for patients in need
- Demonstrate the value of new medications
- Enable better health
YES, WE WILL
Our commitment is unwavering.
We relentlessly pursue and deliver the best solutions to enable access, no matter how challenging the situation. We are resourceful and creative and always going the extra mile.
YES, WE DID
The Challenge:
Reduce the risk of infection in leukemia patients.
LEUKINE®, approved by the US FDA in 1991, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.
In 2018, Partner Therapeutics, Inc. (PTx) acquired the global rights to develop, manufacture, and commercialize Leukine ® (sargramostim) from Sanofi. As a small company, Ptx did not have the internal resources to handle international requests for the drug and didn’t know how they could successfully support patients outside the US, in full regulatory compliance, even though the product was not registered in other geographies.
Read More
YES, WE DID
The Challenge:
Provide free cancer treatment to patients around the world
The Max Foundation is a global non-profit organization focused on increasing the access to treatment, care and support for people living with cancer around the world. In 2017 the Foundation sought to put in place The Max Access Solutions program, a patient-centric care model for delivering free cancer treatment to those in need. The Foundation wanted to be able to offer its patients targeted treatment using a portfolio of oncology medicines from multiple pharmaceutical companies. They sought a partner to handle the distribution, quality assurance and regulatory activities to safely and securely store, handle and deliver the medicines to their patients. After evaluating options for a partner to manage the distribution, Tanner was selected.
Read More
YES, WE DID
The Challenge:
Uninterrupted distribution to patients in Latin America
A major pharmaceutical company divested a mature pipeline asset to a medium size pharma company that did not have a presence in Latin America, but wanted to continue distribution of the product.
Read More
YES, WE DID
The Challenge:
Assuring continuity during a global pandemic
A leading clinical-stage biotechnology company required packs of a comparator to conduct a Phase III trial for their leading asset. They required the stock in a single lot, and because of the ongoing COVID-19 pandemic, wanted stock with a long shelf life and additional assurances regarding the supply chain to minimize lead times and the chance of unexpected manufacturer disruptions.
Read MoreTESTIMONIAL
Tanner Pharma Group is truly an example of what it means to put humanity at the center of their business. This was not just words on a page or some empty mission statement, it’s compassion in action!
They are a prime example on how Pharma should be running their business and focusing their motivation.
Joshua Frase FoundationPROVIDING ACCESS TO
120+
countries with the help of our non-profit collaborators:
RECENT NEWS & EVENTS
-
Building a Culture of Well-Being: A Partnership Between Tanner Pharma Group and Red Dot 365
At Tanner Pharma, our purpose revolves around people. This focus not only includes the patients, physicians, pharma companies and NGO’s we serve and partner with, but our outstanding team members who help us make a difference and positively impact lives around the world. With that in mind, we are continuously seeking ways to support our…
Read More -
Evolving for the Greater Good in the COVID-19 Era
At Tanner, we think of giving not only as a duty but as a privilege. A critical part of our success is that the mission and culture of Tanner Pharma is embodied in each member of our team. Whether it’s through the global programs we develop and manage for our clients, or the fundraising we…
Read More -
From Patient Access to Real World Data – Early Access Programs Offer Compelling Results
What is an EAP? Early Access Programs (EAPs), also referred to as Compassionate Use, Managed Access Programs or Expanded Access Programs, are a pathway by which pharma and biopharmaceutical companies provide investigational new drugs (INDs) to patients with serious conditions. Often, patients have exhausted their approved therapies and cannot participate in a clinical trial. These…
Read More
FEATURE
Max Global Experience: Uganda
Tanner Pharma Group is proud to serve as the title sponsor for The Max Foundation’s 2018 “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa.